XML 77 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisition of Molecular Insight Pharmaceuticals, Inc (Tables)
 12 Months Ended
Dec. 31, 2013
Acquisition of Molecular Insight Pharmaceuticals, Inc [Abstract]  
Schedule Purchase Price Allocation [Table Text Block]
Purchase Price Allocation: We have accounted for the Molecular Insight acquisition by allocating our estimate of the fair market value of the consideration we paid to the fair values of the assets acquired and liabilities assumed at the effective date of the acquisition, estimated using the valuation models summarized below. Given the uniqueness of and uncertainties attendant to the assets and liabilities, the derived values do not reflect actual transactions or quoted prices. Acquired intangible assets, including goodwill, are not deductible for tax purposes.

 
 
Amount
 
Consideration:
 
 
Progenics common stock consideration paid
 
$
11,265
 
Contingent consideration (pursuant to future milestone obligations)
  
15,900
 
Total consideration
  
27,165
 
 
    
Tangible assets acquired and liabilities assumed:
    
Cash and cash equivalents
  
1,888
 
Accounts receivable
  
56
 
Other current assets
  
529
 
Fixed assets
  
249
 
Accounts payable, accrued expenses and deferred revenue - current
  
(2,876
)
Deferred tax liability – long term
  
(12,683
)
Total tangible assets acquired and liabilities assumed
  
(12,837
)
 
    
Intangible assets – in process research and development
  
32,300
 
Total tangible and intangible assets acquired and liabilities assumed
  
19,463
 
 
    
Goodwill
 
$
7,702
 
 
Business Acquisition, Pro Forma Information
Pro forma financial information (unaudited): The following unaudited pro forma information presents the results of operations of the combined companies for the periods indicated as if the acquisition had been consummated on January 1, 2012, combining the respective historical results of Progenics and MIP for each period. Non-recurring transaction expenses of $790, incurred in the year ended December 31, 2013, are reflected in the pro forma information as if these were incurred in the corresponding 2012 period, due to the pro forma assumption of January 1, 2012 as the date of the acquisition consummation.

 
 
Three Months Ended
December 31,
  
Year Ended
December 31,
 
 
 
2013
  
2012
  
2013
  
2012
 
Revenues
 
$
2,968
  
$
12,801
  
$
7,867
  
$
18,235
 
Net loss
  
(8,551
)
  
(3,458
)
  
(43,736
)
  
(57,877
)
Basic and diluted loss per share
  
(0.14
)
  
(0.08
)
  
(0.78
)
  
(1.48
)